| Literature DB >> 25337406 |
Ioannis P Kioumis1, Konstantinos Zarogoulidis1, Haidong Huang1, Qiang Li1, Georgios Dryllis1, Georgia Pitsiou1, Nikolaos Machairiotis1, Nikolaos Katsikogiannis1, Antonis Papaiwannou1, Sofia Lampaki1, Konstantinos Porpodis1, Bojan Zaric1, Perin Branislav1, Ioannis Mpoukovinas1, George Lazaridis1, Paul Zarogoulidis1.
Abstract
Pneumothorax is recognized as a common and life-threatening complication in cystic fibrosis (CF) patients, especially in those who are infected with P. aeruginosa, B. cepacia or Aspergillus, need enteral feeding, are diagnosed as suffering from allergic bronchopulmonary aspergillosis (ABPA), developed massive hemoptysis, and their respiratory function is seriously compromised. Structural impairment and altered airflow dynamics in the lungs of CF patients are considered as the main predisposing factors, but also inhaled medications and non-invasive positive pressure ventilation (NIPPV) could increase the risk of pneumothorax. Clinical presentation could range from dramatic to very mild. Management of spontaneous pneumothorax occurring to patients with CF is essentially similar to that for non-CF patients. Therapeutic options include intercostal tube drainage, video-assisted thoracoscopic surgery (VATS), and medical or surgical pleurodesis. Pneumothorax increases both short- and long-term morbidity and mortality in CF patients and causes significant deterioration of their quality of life.Entities:
Keywords: Cystic fibrosis (CF); antibiotics, macrolides; pneumothorax
Year: 2014 PMID: 25337406 PMCID: PMC4203988 DOI: 10.3978/j.issn.2072-1439.2014.09.27
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895